Speciality: Rheumatology
Description:
A warm welcome to all the medical professionals in this case-based panel discussion on the role of CDK 4/6 inhibitors in clinical practice.
Cyclin-dependent kinase (CDK) 4/6 inhibitors are a class of anticancer medications. It is also helpful in reducing or eliminating endocrine resistance when used in combination with endocrine therapy. It can be used for the treatment of hormone receptor–positive (HR+) breast cancer.
The CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib are observed to enhance the change in the treatment paradigm for patients with HR+/HER2− advanced breast cancer. Moreover, these drugs have demonstrated a meaningful improvement in PFS when used for first- or later-line therapy.
Therefore, listen to the webinar, grab the knowledge that is shared, and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Study opens up possibility of bespoke prostate cancer treatment
2.
Why Encouragement May Not Improve Motivation in Depression
3.
Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients
4.
A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.
5.
Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.
1.
Prevention Through Survivorship-Focused Strategies for Preserving Functional Independence After Cancer
2.
Patient Management for Bone Marrow Functional Recovery Pathways
3.
Uncovering the Causes of Thrombocytosis: A Journey to Improved Health
4.
Targeted Approaches to Breast Cancer Liver Metastases: Surgery, Ablation, and Survival Insights
5.
Hematopoietic Immune Microenvironment Plasticity: Mechanisms, Clinical Implications, and Emerging Therapeutics
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
2.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
4.
Early Cancer Detection Saves Lives
5.
How Platelet Disorders Can Affect the Body
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation